MENLO PARK, Calif., Feb. 12, 2025 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter 2024 following the close of market on Thursday, Feb. 20, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress.
Fourth Quarter 2024 Webcast and Conference Call Details
A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL’s website at investors.grail.com.
Please register for the live event at https://grail-q4-financial-results-2024.open-exchange.net/.
To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit grail.com.
SOURCE GRAIL, Inc.
The global healthtech market is experiencing rapid growth due to increasing health awareness and preventive…
This innovative tech collaboration addresses emotional, logistical and financial challenges associated with international clinical trial…
Jean-Paul Mangeolle joins as Chairman of the Board of DirectorsDavid Newble appointed as an Independent Board MemberLaurence…
HEIDELBERG, Germany, April 15, 2025 /PRNewswire/ -- NEC Laboratories Europe and Data-Driven.AI are working together to…
Created to distinguish the most remarkable scientific discoveries in the biomedical field, this international award has…
WELL achieved annual revenue of $919.7 million in 2024, an increase of 19% compared to…